Email not displaying correctly? View it in your browser.
August 2017

  The TCRN is a translational cancer research centre program funded by the Cancer Institute NSW Cancer Institute NSW  
bullet Welcome to the Nexus for August 2017

In this edition, we are pleased to announce the opportunity to apply for a TCRN fully funded scholarship with a focus on translational cancer research. We also congratulate Professor John Pimanda and his team for their recent success in being awarded the inaugural TCRN Flagship Support Grant for 2017 as well as learn from the experiences of the recent TCRN conference grant recipient Toni Rose Jue.

There are a number of events on the horizon that may be of interest to many members such as the Health-Science Alliance Symposium themed ‘Future of the Clinical Academic’ in October and the NSW Premier’s Awards for Outstanding Cancer Research 2017 in November. Finally, we have some recent publications from TCRN Members to share with you.

TCRN_symbol_transparent_hi-res PhD Scholarships in Translational Cancer Research

The TCRN seeks expressions of interest for a fully funded TCRN scholarship, top-up and research costs commencing Semester 1 2018.

Click here to learn more and apply

Professor John Pimandas Group TCRN Flagship Support Grant - Congratulations to John Pimanda and Team

The TCRN is delighted to announce that the inaugural Flagship Support Grant has been awarded to Professor John Pimanda for his project: A flowcytometry based assay to predict Azacitidine (AZA) responsiveness in Myelodysplasia/Acute Myeloid Leukemia (MDS/AML).

Discover more

Toni_Jue TCRN Travel story | Toni Jue 2017 R1 Conference Grant

Read all about Toni Rose Jue's recent experience attending The 5th Quadrennial Meeting of the World Federation of Neuro-oncology Societies, where she discovered that her work on profoundly enhancing quality of life and survival rates for people with Glioblastoma was well received by her international colleagues as it is unique in the field.

Learn about her journey

18_pimanda_shutterstock_1 Improving the “wait and see” approach in MDS blood cancer treatment

Every day, four Australians are diagnosed with myelodysplastic syndrome (MDS), but many people's resistance to the best available treatment has been poorly understood until now.

Researchers are closer to helping the 50% of people with a group of blood disorders that can transform into acute leukemia but who don’t respond to the best available treatment.

Learn more

bal.JPG The TCRN is pleased to welcome our new Program Coordinator Ballant Kojo Eyeson-Annan to the Operations and Project Team.

Ballant is responsible for managing the TCRN membership base as well as the promotion of the TCRN through our website and social media channels. He coordinates member communications, networking events and educational activities for the TCRN.

Find out more

HSA logo Health-Science Alliance Symposium ‘Future of the Clinical Academic’

The Sixth Annual Health-Science Alliance Symposium ‘Future of the Clinical Academic’ will be held on Friday, 20 October 2017. Please register early to ensure that you don't miss out on the limited spaces available.

Register now!

Screen Shot 2017-07-19 at 8.33.16 am The NSW Premier’s Awards for Outstanding Cancer Research 2017

Save the date November 3rd 2017

The NSW Premier’s Awards for Outstanding Cancer Research, hosted by the Cancer Institute NSW, honours the achievements of the individuals and teams that work across the cancer research sector to lessen the impact of cancer. Nominations will open very soon and tickets for the event will be on sale from early September.

Find out more

books research study  iStock_93320821_LARGE_1 Recent interesting articles from TCRN members

In this monthly article the TCRN Operations & Projects team use on-line tools to identify publications attributed to TCRN members. We are using Scopus, the largest abstract and citation database of peer-reviewed literature as our primary source.

Read the latest articles here

Missed the last TCRN Nexus Newsletter?
You can view it here.